Chris I Jones1, Alison H Goodall. 1. The Department of Cardiac Sciences, University of Leicester, CSB Glenfield Hospital NHS Trust Groby Road, Leicester, LE3 9QP, UK. cij1@le.ac.uk
Abstract
INTRODUCTION: Contrast media (CM) possess both pro-thrombotic and anticoagulant properties. Here we investigate the effect of three classes of CM; Iohexol, Iodixanol and Ioxaglate, on thrombus formation and fibrinolysis in vitro and evaluated the contribution of platelets to this process. MATERIALS AND METHODS: Non-anticoagulated blood was mixed with CM or saline (50% or 20% (v/v)) for 1 min then citrated. Thrombi were produced in vitro under flow in a Chandler loop. Thrombus structure was visualized by immunohistochemistry using FITC-fibrin/ogen antibodies, and propidium iodide to identify nucleated blood cells. To measure fibrino/thrombolysis release of FITC-labeled fibrinogen, added prior to thrombus formation, was measured over 24 h. Platelet degranulation was analyzed by whole blood flow-cytometry. RESULTS: No thrombi formed from blood incubated with Ioxaglate. Thrombi formed with Iohexol or Iodixanol weighed > OR = 10x more than saline controls (116+/-52 and 230+/-128 mg vs. 11+/-3 mg, respectively; p<0.0005), and were more resistant to thrombolysis as evidenced by the release of FITC over 24 h (19.1+/-8.9 and 31.9+/-17.2 U vs. 65.1+/-19.1 U, respectively; p<0.02). Thrombi formed with Iodixanol and Iohexol had larger, more diffuse platelet-rich head areas and tail regions composed of a more open fibrinogen/fibrin meshwork enclosing denser RBC rich areas compared to controls. Iodixanol and Ioxaglate did not increase platelet degranulation, but Iohexol caused a significant increase compared to the saline control (percentage of platelets expressing P-selectin 68.9+/-23.43% vs. 4.93+/-1.44%, respectively; p=0.001). CONCLUSION: Thus thrombi formed with Iodixanol or Iohexol will be larger and more resistant to thrombolysis, whereas Ioxaglate may reduce the risk of thrombus formation.
INTRODUCTION: Contrast media (CM) possess both pro-thrombotic and anticoagulant properties. Here we investigate the effect of three classes of CM; Iohexol, Iodixanol and Ioxaglate, on thrombus formation and fibrinolysis in vitro and evaluated the contribution of platelets to this process. MATERIALS AND METHODS: Non-anticoagulated blood was mixed with CM or saline (50% or 20% (v/v)) for 1 min then citrated. Thrombi were produced in vitro under flow in a Chandler loop. Thrombus structure was visualized by immunohistochemistry using FITC-fibrin/ogen antibodies, and propidium iodide to identify nucleated blood cells. To measure fibrino/thrombolysis release of FITC-labeled fibrinogen, added prior to thrombus formation, was measured over 24 h. Platelet degranulation was analyzed by whole blood flow-cytometry. RESULTS: No thrombi formed from blood incubated with Ioxaglate. Thrombi formed with Iohexol or Iodixanol weighed > OR = 10x more than saline controls (116+/-52 and 230+/-128 mg vs. 11+/-3 mg, respectively; p<0.0005), and were more resistant to thrombolysis as evidenced by the release of FITC over 24 h (19.1+/-8.9 and 31.9+/-17.2 U vs. 65.1+/-19.1 U, respectively; p<0.02). Thrombi formed with Iodixanol and Iohexol had larger, more diffuse platelet-rich head areas and tail regions composed of a more open fibrinogen/fibrin meshwork enclosing denser RBC rich areas compared to controls. Iodixanol and Ioxaglate did not increase platelet degranulation, but Iohexol caused a significant increase compared to the saline control (percentage of platelets expressing P-selectin 68.9+/-23.43% vs. 4.93+/-1.44%, respectively; p=0.001). CONCLUSION: Thus thrombi formed with Iodixanol or Iohexol will be larger and more resistant to thrombolysis, whereas Ioxaglate may reduce the risk of thrombus formation.
Authors: Peter Aspelin; Fulvio Stacul; Henrik S Thomsen; Sameh K Morcos; Aart J van der Molen Journal: Eur Radiol Date: 2006-01-05 Impact factor: 5.315
Authors: T A Tomsick; P Khatri; T Jovin; B Demaerschalk; T Malisch; A Demchuk; M D Hill; E Jauch; J Spilker; J P Broderick Journal: Neurology Date: 2010-03-30 Impact factor: 9.910
Authors: Yuko Kurosawa; Aigang Lu; Pooja Khatri; Janice A Carrozzella; Joseph F Clark; Jane Khoury; Thomas A Tomsick Journal: Stroke Date: 2010-04-01 Impact factor: 7.914
Authors: J S Wang; J Diaz; A Sabokbar; N Athanasou; F Kjellson; K E Tanner; I D McCarthy; L Lidgren Journal: J R Soc Interface Date: 2005-03-22 Impact factor: 4.118
Authors: T A Tomsick; L D Foster; D S Liebeskind; M D Hill; J Carrozella; M Goyal; R von Kummer; A M Demchuk; I Dzialowski; V Puetz; T Jovin; H Morales; Y Y Palesch; J Broderick; P Khatri; S D Yeatts Journal: AJNR Am J Neuroradiol Date: 2015-07-30 Impact factor: 3.825
Authors: Mark M McDonald; Joancy M Archeval-Lao; Chunyan Cai; Hui Peng; Navdeep Sangha; Stephanie A Parker; Jeremy Wetzel; Stephen A Riney; Matt F Cherches; Greer J Guthrie; Tiffany C Roper; Jorge F Kawano-Castillo; Renga Pandurengan; Mohammad H Rahbar; James C Grotta Journal: Stroke Date: 2013-12-26 Impact factor: 7.914